[GLP1 receptor agonist drug treatments and adult obesity]

Abstract

Obesity is a chronic disease with multiple causes and serious complications. Treatments include lifestyle modifications and, for severe cases, medication. Today, molecules such as liraglutide and semaglutide are showing promising results in terms of weight loss and even cardiovascular benefits (for the latter), although reimbursement is limited in France. The dual agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptors (tirzepatide) also offers encouraging prospects. Research is continuing with bi- and tri-agonists to improve the management of obesity.

Keywords: glucagon intestinal peptide; glucagon-like peptide 1; liraglutide; semaglutide; sémaglutide; tirzepatide; tirzépatide.